In PV, ON-GNPs targeting TLR9, IRF7, and IL-8 pathways may reduce thrombotic risk and leukocytosis, while in ET, they could mitigate platelet activation and chronic inflammation. This evidence concerns the gene CXCL8 and essential thrombocythemia.